Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

This content was produced independently by The American Journal of Managed Care^® and is not endorsed by the American Academy of Dermatology.

EP: 1.Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

EP: 2.Upcoming Generics Provide New Considerations and Opportunities for Savings

EP: 3.Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

Now Viewing

EP: 4.Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

EP: 5.Dermatologists’ Focus to Delve Below the Skin at Annual Conference

EP: 6.Experts Herald “Year of the JAK Inhibitor” in Dermatology

EP: 7.Dr Monica Li Highlights Advances in Microneedling

EP: 8.Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years

EP: 9.Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

EP: 10.Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

EP: 11.Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo

EP: 12.Examining Dermatological Care for Transgender Patients

EP: 13.How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies

EP: 14.Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa

EP: 15.Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis

EP: 16.Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

EP: 17.Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection

EP: 18.Studies Presented at AAD Examine Safety and Satisfaction of Tildrakizumab for Psoriasis

EP: 19.Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky

EP: 20.Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

EP: 21.Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch

EP: 22.Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

EP: 23.Panel Discusses Treating Acne, Psoriasis in Dermatology Patients

EP: 24.New and Upcoming Treatment for Vitiligo, Atopic Dermatitis

EP: 25.Long-Term Safety of Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

EP: 26.Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment

EP: 27.ICYMI: Highlights From RAD 2023

EP: 28.AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics

EP: 29.Dr Amy Paller Previews the 2024 AAD Annual Conference

EP: 30.Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

EP: 31.Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

EP: 32.Atopic Dermatitis in Adults: Challenges and Treatment Strategies

EP: 33.Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

EP: 34.Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

EP: 35.Skin Tone Bias Persists in Google Searches for Vitiligo

EP: 36.Management of HS Requires Both Coordination, Communication Between Patients and Providers

EP: 37.Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

EP: 38.Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

EP: 39.Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

EP: 40.Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 41.Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

EP: 42.New Study Links Social Factors to Hidradenitis Suppurativa Severity

EP: 43.Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

EP: 44.Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

EP: 45.Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

EP: 46.Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

EP: 47.Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

EP: 48.Autoimmune Comorbidities Prevalent in Patients With Vitiligo

EP: 49.Skin Cancer Incidence Highest Among Rural, SOC Individuals

EP: 50.Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

EP: 51.Gaps in Skincare Knowledge, Sun Protection Practice Exist Among Patients With Lupus

EP: 52.Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD

EP: 53.Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

EP: 54.Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

EP: 55.Dr Monica Li Lists Microneedling Considerations, Precautions

EP: 56.Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 57.Dr Lawrence Eichenfield Discusses Positive Results of Roflumilast Cream 0.05% in Pediatric Patients With AD

EP: 58.Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

EP: 59.Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

EP: 60.Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

EP: 61.Dr Martina Porter Shares Findings on Ruxolitinib Cream in Patients With HS

EP: 62.Dr Martin Dahl Summarizes Findings, Limitations of Study Analyzing ANB032 Use in Patients With AD

After last year’s annual meeting of the American Academy of Dermatology (AAD), the FDA approved the first new treatment for vitiligo, which means this year’s meeting is the first time to talk about it. In addition, there is a lot of research in the space and a lot of opportunity for treatment in the near future, said John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.

In addition to speaking in multiple sessions on vitiligo, Harris will be presenting the results of the withdrawal arm of the TRuE-V extension study of ruxolitinib cream in vitiligo. The meeting with take place March 17-21 in New Orleans, Louisiana.

Transcript

What are you presenting at the upcoming annual meeting of the American Academy of Dermatology, and what are you looking forward to at the meeting?

Yeah, I’m excited about the AAD this year, specifically for vitiligo. I'm talking a lot about vitiligo in a number of different sessions, with different angles depending on the session, whether it's the vitiligo symposium itself or a translational research symposium, or a skin-of-color symposium, or a JAK [Janus kinase] inhibitor symposium. There are a lot of reasons to talk about vitiligo.

The reason I'm excited is because we've been treating vitiligo for thousands of years. Interestingly, it started in the Iron Age, and we’ve recognized the disease for a long time, and we haven't seen novel treatments until very recently. So, the past 10 to 15 years, new research has really launched new opportunities, and we saw our first FDA-approved treatment for vitiligo, to treat and repigment the skin, last summer. That was after the last AAD, so we get to announce this new, first FDA-approved treatment.

That's just the tip of the iceberg. So that was a phase 2 and 3 clinical trial that provided the rationale for FDA approval.Wwe're doing more clinical trials now discovering new pathways to target, and so we see a lot of opportunity coming in the near future as well.